Rani Therapeutics Holdings (RANI) Free Cash Flow (2020 - 2026)

Rani Therapeutics Holdings has reported Free Cash Flow for 7 years, with the latest figure at -$9.1 million in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 55.24% year-over-year to -$9.1 million in Q2 2026; TTM through Jun 2026 was -$20.3 million, a 34.92% increase from a year earlier, with the FY2025 full-year figure at -$18.8 million, up 47.43% from the prior year.
• Free Cash Flow was -$9.1 million for Q2 2026 at Rani Therapeutics Holdings, down from -$6.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $294000.0 in Q4 2025, with the low at -$15.2 million in Q4 2022.
• Average Free Cash Flow over 5 years is -$9.5 million, with a median of -$9.3 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 131.83% in 2022, then jumped 103.38% in 2025.
• Over 5 years, Free Cash Flow stood at -$15.2 million in 2022, then climbed by 16.58% to -$12.6 million in 2023, then surged by 31.31% to -$8.7 million in 2024, then surged by 103.38% to $294000.0 in 2025, then slumped by 3179.93% to -$9.1 million in 2026.
• The last three Free Cash Flow figures came in at -$9.1 million (Q2 2026), -$6.5 million (Q1 2026), and $294000.0 (Q4 2025), per Business Quant data.